nodes	percent_of_prediction	percent_of_DWPC	metapath
Nafarelin—Pulmonary fibrosis—Bleomycin—melanoma	0.0141	0.0228	CcSEcCtD
Nafarelin—Traumatic liver injury—Temozolomide—melanoma	0.0141	0.0227	CcSEcCtD
Nafarelin—Ascites—Dactinomycin—melanoma	0.0128	0.0206	CcSEcCtD
Nafarelin—Pulmonary fibrosis—Carmustine—melanoma	0.0123	0.0199	CcSEcCtD
Nafarelin—GNRHR—Peptide GPCRs—CXCR1—melanoma	0.012	0.0314	CbGpPWpGaD
Nafarelin—Pulmonary fibrosis—Temozolomide—melanoma	0.0119	0.0193	CcSEcCtD
Nafarelin—GNRHR—Peptide GPCRs—MC1R—melanoma	0.0118	0.031	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—CCR7—melanoma	0.0113	0.0297	CbGpPWpGaD
Nafarelin—Interstitial pneumonia—Temozolomide—melanoma	0.0109	0.0175	CcSEcCtD
Nafarelin—Transient ischaemic attack—Temozolomide—melanoma	0.0104	0.0168	CcSEcCtD
Nafarelin—GNRHR—GPCRs, Other—CXCR1—melanoma	0.0101	0.0266	CbGpPWpGaD
Nafarelin—GNRHR—GPCRs, Other—GRM1—melanoma	0.00957	0.0252	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—CXCR2—melanoma	0.00936	0.0246	CbGpPWpGaD
Nafarelin—Rash maculo-papular—Vemurafenib—melanoma	0.00934	0.0151	CcSEcCtD
Nafarelin—Neoplasm—Vemurafenib—melanoma	0.00929	0.015	CcSEcCtD
Nafarelin—Interstitial lung disease—Bleomycin—melanoma	0.00879	0.0142	CcSEcCtD
Nafarelin—Myasthenia—Carmustine—melanoma	0.00864	0.014	CcSEcCtD
Nafarelin—Deep vein thrombosis—Temozolomide—melanoma	0.00863	0.0139	CcSEcCtD
Nafarelin—Pulmonary fibrosis—Docetaxel—melanoma	0.00794	0.0128	CcSEcCtD
Nafarelin—GNRHR—GPCRs, Other—CXCR2—melanoma	0.00793	0.0208	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—PLCB4—melanoma	0.00776	0.0204	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—EDNRB—melanoma	0.00771	0.0202	CbGpPWpGaD
Nafarelin—Ascites—Docetaxel—melanoma	0.00768	0.0124	CcSEcCtD
Nafarelin—Interstitial lung disease—Carmustine—melanoma	0.00767	0.0124	CcSEcCtD
Nafarelin—Interstitial lung disease—Temozolomide—melanoma	0.00742	0.012	CcSEcCtD
Nafarelin—Interstitial pneumonia—Docetaxel—melanoma	0.00722	0.0117	CcSEcCtD
Nafarelin—Vaginal haemorrhage—Temozolomide—melanoma	0.00709	0.0114	CcSEcCtD
Nafarelin—Menorrhagia—Temozolomide—melanoma	0.00709	0.0114	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PLCB4—melanoma	0.00694	0.0182	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—CXCR4—melanoma	0.00684	0.018	CbGpPWpGaD
Nafarelin—Dry skin—Vemurafenib—melanoma	0.00683	0.011	CcSEcCtD
Nafarelin—GNRHR—GPCRs, Other—F2R—melanoma	0.00674	0.0177	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—F2RL1—melanoma	0.0066	0.0173	CbGpPWpGaD
Nafarelin—Liver injury—Temozolomide—melanoma	0.00624	0.0101	CcSEcCtD
Nafarelin—Cystitis noninfective—Bleomycin—melanoma	0.00608	0.00981	CcSEcCtD
Nafarelin—Breast pain—Temozolomide—melanoma	0.00602	0.00971	CcSEcCtD
Nafarelin—Cystitis—Bleomycin—melanoma	0.00601	0.0097	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—F2RL1—melanoma	0.0059	0.0155	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—KISS1—melanoma	0.00588	0.0155	CbGpPWpGaD
Nafarelin—Weight decreased—Vemurafenib—melanoma	0.00583	0.00941	CcSEcCtD
Nafarelin—Deep vein thrombosis—Docetaxel—melanoma	0.00574	0.00926	CcSEcCtD
Nafarelin—Herpes simplex—Temozolomide—melanoma	0.0057	0.0092	CcSEcCtD
Nafarelin—Bladder pain—Bleomycin—melanoma	0.00563	0.00908	CcSEcCtD
Nafarelin—Coordination abnormal—Carmustine—melanoma	0.00553	0.00893	CcSEcCtD
Nafarelin—Pulmonary embolism—Carmustine—melanoma	0.00543	0.00877	CcSEcCtD
Nafarelin—GNRHR—G alpha (q) signalling events—GRM1—melanoma	0.00538	0.0141	CbGpPWpGaD
Nafarelin—Coordination abnormal—Temozolomide—melanoma	0.00535	0.00863	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—melanoma	0.00526	0.0138	CbGpPWpGaD
Nafarelin—Pulmonary embolism—Temozolomide—melanoma	0.00525	0.00848	CcSEcCtD
Nafarelin—Urinary incontinence—Carmustine—melanoma	0.00524	0.00847	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—TAS2R60—melanoma	0.00517	0.0136	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL1—melanoma	0.00514	0.0135	CbGpPWpGaD
Nafarelin—Urinary incontinence—Temozolomide—melanoma	0.00507	0.00818	CcSEcCtD
Nafarelin—Interstitial lung disease—Docetaxel—melanoma	0.00493	0.00796	CcSEcCtD
Nafarelin—Neoplasm—Carmustine—melanoma	0.00491	0.00793	CcSEcCtD
Nafarelin—Gynaecomastia—Carmustine—melanoma	0.00486	0.00785	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—melanoma	0.00481	0.0126	CbGpPWpGaD
Nafarelin—Neoplasm—Temozolomide—melanoma	0.00475	0.00766	CcSEcCtD
Nafarelin—Cerebrovascular accident—Bleomycin—melanoma	0.00461	0.00744	CcSEcCtD
Nafarelin—Pleural effusion—Docetaxel—melanoma	0.00456	0.00736	CcSEcCtD
Nafarelin—Alopecia—Vemurafenib—melanoma	0.00456	0.00736	CcSEcCtD
Nafarelin—Malnutrition—Vemurafenib—melanoma	0.00449	0.00725	CcSEcCtD
Nafarelin—Ear pain—Temozolomide—melanoma	0.00447	0.00721	CcSEcCtD
Nafarelin—Dysgeusia—Vemurafenib—melanoma	0.0044	0.0071	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—F2RL1—melanoma	0.00437	0.0115	CbGpPWpGaD
Nafarelin—Eye pain—Carmustine—melanoma	0.00437	0.00705	CcSEcCtD
Nafarelin—Eye pain—Temozolomide—melanoma	0.00422	0.00681	CcSEcCtD
Nafarelin—Hot flush—Temozolomide—melanoma	0.00407	0.00658	CcSEcCtD
Nafarelin—Menopausal symptoms—Temozolomide—melanoma	0.00404	0.00652	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CXCL1—melanoma	0.00391	0.0103	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—KISS1—melanoma	0.0039	0.0102	CbGpPWpGaD
Nafarelin—Myalgia—Vemurafenib—melanoma	0.00382	0.00617	CcSEcCtD
Nafarelin—Arthralgia—Vemurafenib—melanoma	0.00382	0.00617	CcSEcCtD
Nafarelin—GNRHR—G alpha (q) signalling events—F2R—melanoma	0.00379	0.00996	CbGpPWpGaD
Nafarelin—Oliguria—Docetaxel—melanoma	0.00379	0.00612	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR1—melanoma	0.00377	0.00991	CbGpPWpGaD
Nafarelin—Affect lability—Temozolomide—melanoma	0.00375	0.00606	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—MC1R—melanoma	0.00372	0.00976	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—EDNRB—melanoma	0.00367	0.00965	CbGpPWpGaD
Nafarelin—Mood swings—Temozolomide—melanoma	0.00361	0.00583	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCR7—melanoma	0.00356	0.00936	CbGpPWpGaD
Nafarelin—Weight decreased—Bleomycin—melanoma	0.00353	0.0057	CcSEcCtD
Nafarelin—Dry skin—Temozolomide—melanoma	0.00349	0.00564	CcSEcCtD
Nafarelin—Pulmonary embolism—Docetaxel—melanoma	0.00349	0.00564	CcSEcCtD
Nafarelin—Muscular weakness—Carmustine—melanoma	0.00348	0.00561	CcSEcCtD
Nafarelin—GNRHR—G alpha (q) signalling events—GNA11—melanoma	0.00347	0.00911	CbGpPWpGaD
Nafarelin—Acute coronary syndrome—Bleomycin—melanoma	0.00343	0.00554	CcSEcCtD
Nafarelin—Myocardial infarction—Bleomycin—melanoma	0.00341	0.00551	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—F2R—melanoma	0.00339	0.00891	CbGpPWpGaD
Nafarelin—Muscular weakness—Temozolomide—melanoma	0.00336	0.00543	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00334	0.00539	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—F2RL1—melanoma	0.00333	0.00874	CbGpPWpGaD
Nafarelin—Abdominal distension—Temozolomide—melanoma	0.00332	0.00535	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRB—melanoma	0.00328	0.00863	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—GNAQ—melanoma	0.00322	0.00847	CbGpPWpGaD
Nafarelin—Sweating increased—Temozolomide—melanoma	0.00321	0.00518	CcSEcCtD
Nafarelin—Decreased appetite—Vemurafenib—melanoma	0.00319	0.00514	CcSEcCtD
Nafarelin—Neoplasm—Docetaxel—melanoma	0.00316	0.0051	CcSEcCtD
Nafarelin—Constipation—Vemurafenib—melanoma	0.00313	0.00506	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—GRM3—melanoma	0.00313	0.00822	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—melanoma	0.0031	0.00815	CbGpPWpGaD
Nafarelin—Dysuria—Temozolomide—melanoma	0.00308	0.00497	CcSEcCtD
Nafarelin—Depression—Carmustine—melanoma	0.00303	0.00489	CcSEcCtD
Nafarelin—Weight increased—Temozolomide—melanoma	0.003	0.00484	CcSEcCtD
Nafarelin—Weight decreased—Temozolomide—melanoma	0.00298	0.00481	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—KISS1—melanoma	0.00297	0.00779	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR2—melanoma	0.00295	0.00776	CbGpPWpGaD
Nafarelin—Depression—Temozolomide—melanoma	0.00293	0.00473	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—TAS2R60—melanoma	0.00292	0.00767	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—melanoma	0.00288	0.00757	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCR1—melanoma	0.00287	0.00755	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—MC1R—melanoma	0.00283	0.00744	CbGpPWpGaD
Nafarelin—Alopecia—Bleomycin—melanoma	0.00276	0.00446	CcSEcCtD
Nafarelin—Sinusitis—Temozolomide—melanoma	0.00275	0.00445	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—GRM1—melanoma	0.00271	0.00713	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CCR7—melanoma	0.00271	0.00713	CbGpPWpGaD
Nafarelin—Hot flush—Docetaxel—melanoma	0.00271	0.00437	CcSEcCtD
Nafarelin—Menopausal symptoms—Docetaxel—melanoma	0.00269	0.00434	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—TAS2R60—melanoma	0.00265	0.00696	CbGpPWpGaD
Nafarelin—Asthenia—Vemurafenib—melanoma	0.00263	0.00424	CcSEcCtD
Nafarelin—Pruritus—Vemurafenib—melanoma	0.00259	0.00419	CcSEcCtD
Nafarelin—Alopecia—Dactinomycin—melanoma	0.00258	0.00416	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—F2R—melanoma	0.00251	0.0066	CbGpPWpGaD
Nafarelin—Diarrhoea—Vemurafenib—melanoma	0.00251	0.00405	CcSEcCtD
Nafarelin—GNRHR—G alpha (q) signalling events—EDN1—melanoma	0.0025	0.00657	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—EDNRB—melanoma	0.00243	0.00639	CbGpPWpGaD
Nafarelin—Dizziness—Vemurafenib—melanoma	0.00242	0.00391	CcSEcCtD
Nafarelin—Alopecia—Carmustine—melanoma	0.00241	0.00389	CcSEcCtD
Nafarelin—Mental disorder—Carmustine—melanoma	0.00239	0.00386	CcSEcCtD
Nafarelin—Malnutrition—Carmustine—melanoma	0.00237	0.00383	CcSEcCtD
Nafarelin—Vomiting—Vemurafenib—melanoma	0.00233	0.00376	CcSEcCtD
Nafarelin—Alopecia—Temozolomide—melanoma	0.00233	0.00376	CcSEcCtD
Nafarelin—Dry skin—Docetaxel—melanoma	0.00232	0.00375	CcSEcCtD
Nafarelin—Myalgia—Bleomycin—melanoma	0.00232	0.00374	CcSEcCtD
Nafarelin—Chest pain—Bleomycin—melanoma	0.00232	0.00374	CcSEcCtD
Nafarelin—Rash—Vemurafenib—melanoma	0.00231	0.00373	CcSEcCtD
Nafarelin—Mental disorder—Temozolomide—melanoma	0.00231	0.00373	CcSEcCtD
Nafarelin—Dermatitis—Vemurafenib—melanoma	0.00231	0.00373	CcSEcCtD
Nafarelin—Headache—Vemurafenib—melanoma	0.0023	0.00371	CcSEcCtD
Nafarelin—Malnutrition—Temozolomide—melanoma	0.00229	0.0037	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CXCR2—melanoma	0.00225	0.00591	CbGpPWpGaD
Nafarelin—Dysgeusia—Temozolomide—melanoma	0.00225	0.00363	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—melanoma	0.00224	0.00587	CbGpPWpGaD
Nafarelin—Oedema—Bleomycin—melanoma	0.00222	0.00358	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PLCB4—melanoma	0.00221	0.00581	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL1—melanoma	0.00221	0.00581	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—WNT5A—melanoma	0.00218	0.00572	CbGpPWpGaD
Nafarelin—Nausea—Vemurafenib—melanoma	0.00218	0.00351	CcSEcCtD
Nafarelin—Myalgia—Dactinomycin—melanoma	0.00216	0.00349	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR4—melanoma	0.00216	0.00567	CbGpPWpGaD
Nafarelin—Anorexia—Bleomycin—melanoma	0.00212	0.00342	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCA—melanoma	0.00209	0.0055	CbGpPWpGaD
Nafarelin—Oedema—Dactinomycin—melanoma	0.00207	0.00334	CcSEcCtD
Nafarelin—Vertigo—Temozolomide—melanoma	0.00206	0.00333	CcSEcCtD
Nafarelin—Convulsion—Carmustine—melanoma	0.00206	0.00332	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K2—melanoma	0.00205	0.00538	CbGpPWpGaD
Nafarelin—Palpitations—Temozolomide—melanoma	0.00203	0.00327	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Bleomycin—melanoma	0.00202	0.00327	CcSEcCtD
Nafarelin—Myalgia—Carmustine—melanoma	0.00202	0.00326	CcSEcCtD
Nafarelin—Chest pain—Carmustine—melanoma	0.00202	0.00326	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CXCL1—melanoma	0.00201	0.00528	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PLCB4—melanoma	0.00201	0.00528	CbGpPWpGaD
Nafarelin—Paraesthesia—Bleomycin—melanoma	0.00199	0.00322	CcSEcCtD
Nafarelin—Weight increased—Docetaxel—melanoma	0.00199	0.00322	CcSEcCtD
Nafarelin—Convulsion—Temozolomide—melanoma	0.00199	0.00321	CcSEcCtD
Nafarelin—Weight decreased—Docetaxel—melanoma	0.00198	0.0032	CcSEcCtD
Nafarelin—Dyspnoea—Bleomycin—melanoma	0.00198	0.0032	CcSEcCtD
Nafarelin—Anorexia—Dactinomycin—melanoma	0.00197	0.00319	CcSEcCtD
Nafarelin—Arthralgia—Temozolomide—melanoma	0.00195	0.00315	CcSEcCtD
Nafarelin—Myalgia—Temozolomide—melanoma	0.00195	0.00315	CcSEcCtD
Nafarelin—Oedema—Carmustine—melanoma	0.00194	0.00313	CcSEcCtD
Nafarelin—Decreased appetite—Bleomycin—melanoma	0.00193	0.00312	CcSEcCtD
Nafarelin—Acute coronary syndrome—Docetaxel—melanoma	0.00192	0.00311	CcSEcCtD
Nafarelin—Myocardial infarction—Docetaxel—melanoma	0.00191	0.00309	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—F2R—melanoma	0.00191	0.00502	CbGpPWpGaD
Nafarelin—Conjunctivitis—Docetaxel—melanoma	0.0019	0.00306	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00189	0.00305	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—F2RL1—melanoma	0.00188	0.00494	CbGpPWpGaD
Nafarelin—Oedema—Temozolomide—melanoma	0.00187	0.00302	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—EDNRB—melanoma	0.00185	0.00486	CbGpPWpGaD
Nafarelin—Anorexia—Carmustine—melanoma	0.00185	0.00298	CcSEcCtD
Nafarelin—Epistaxis—Docetaxel—melanoma	0.00184	0.00297	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—MYO7A—melanoma	0.00184	0.00484	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—DRAP1—melanoma	0.00184	0.00484	CbGpPWpGaD
Nafarelin—Hyperhidrosis—Temozolomide—melanoma	0.00181	0.00292	CcSEcCtD
Nafarelin—Decreased appetite—Dactinomycin—melanoma	0.0018	0.00291	CcSEcCtD
Nafarelin—Anorexia—Temozolomide—melanoma	0.00179	0.00288	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—GRM3—melanoma	0.00177	0.00465	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Carmustine—melanoma	0.00177	0.00285	CcSEcCtD
Nafarelin—Urticaria—Bleomycin—melanoma	0.00176	0.00285	CcSEcCtD
Nafarelin—Rhinitis—Docetaxel—melanoma	0.00176	0.00284	CcSEcCtD
Nafarelin—Insomnia—Carmustine—melanoma	0.00175	0.00283	CcSEcCtD
Nafarelin—Paraesthesia—Carmustine—melanoma	0.00174	0.00281	CcSEcCtD
Nafarelin—Dyspnoea—Carmustine—melanoma	0.00173	0.00279	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—F2RL1—melanoma	0.00171	0.00449	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Temozolomide—melanoma	0.00171	0.00275	CcSEcCtD
Nafarelin—Insomnia—Temozolomide—melanoma	0.00169	0.00273	CcSEcCtD
Nafarelin—Decreased appetite—Carmustine—melanoma	0.00168	0.00272	CcSEcCtD
Nafarelin—Paraesthesia—Temozolomide—melanoma	0.00168	0.00271	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—KISS1—melanoma	0.00168	0.0044	CbGpPWpGaD
Nafarelin—Dyspnoea—Temozolomide—melanoma	0.00167	0.0027	CcSEcCtD
Nafarelin—Constipation—Carmustine—melanoma	0.00166	0.00268	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—EDN1—melanoma	0.00166	0.00435	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCR4—melanoma	0.00164	0.00432	CbGpPWpGaD
Nafarelin—Decreased appetite—Temozolomide—melanoma	0.00163	0.00263	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—CXCR1—melanoma	0.00162	0.00427	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GRM3—melanoma	0.00161	0.00422	CbGpPWpGaD
Nafarelin—Constipation—Temozolomide—melanoma	0.0016	0.00259	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—MC1R—melanoma	0.0016	0.0042	CbGpPWpGaD
Nafarelin—Asthenia—Bleomycin—melanoma	0.00159	0.00257	CcSEcCtD
Nafarelin—Pruritus—Bleomycin—melanoma	0.00157	0.00254	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—TAS2R60—melanoma	0.00157	0.00411	CbGpPWpGaD
Nafarelin—Alopecia—Docetaxel—melanoma	0.00155	0.0025	CcSEcCtD
Nafarelin—Mental disorder—Docetaxel—melanoma	0.00154	0.00248	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—GRM1—melanoma	0.00153	0.00403	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CCR7—melanoma	0.00153	0.00403	CbGpPWpGaD
Nafarelin—Malnutrition—Docetaxel—melanoma	0.00153	0.00246	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—KISS1—melanoma	0.00152	0.004	CbGpPWpGaD
Nafarelin—Dysgeusia—Docetaxel—melanoma	0.00149	0.00241	CcSEcCtD
Nafarelin—Urticaria—Temozolomide—melanoma	0.00149	0.0024	CcSEcCtD
Nafarelin—Asthenia—Dactinomycin—melanoma	0.00149	0.0024	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CXCR1—melanoma	0.00147	0.00387	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—MC1R—melanoma	0.00145	0.00382	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—melanoma	0.00145	0.00381	CbGpPWpGaD
Nafarelin—Diarrhoea—Dactinomycin—melanoma	0.00142	0.00229	CcSEcCtD
Nafarelin—Vomiting—Bleomycin—melanoma	0.00141	0.00228	CcSEcCtD
Nafarelin—Rash—Bleomycin—melanoma	0.0014	0.00226	CcSEcCtD
Nafarelin—Dermatitis—Bleomycin—melanoma	0.0014	0.00226	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—RHOB—melanoma	0.0014	0.00367	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GRM1—melanoma	0.00139	0.00366	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CCR7—melanoma	0.00139	0.00366	CbGpPWpGaD
Nafarelin—Asthenia—Carmustine—melanoma	0.00139	0.00224	CcSEcCtD
Nafarelin—Palpitations—Docetaxel—melanoma	0.00135	0.00218	CcSEcCtD
Nafarelin—Asthenia—Temozolomide—melanoma	0.00134	0.00217	CcSEcCtD
Nafarelin—Diarrhoea—Carmustine—melanoma	0.00133	0.00214	CcSEcCtD
Nafarelin—Pruritus—Temozolomide—melanoma	0.00132	0.00214	CcSEcCtD
Nafarelin—Convulsion—Docetaxel—melanoma	0.00132	0.00213	CcSEcCtD
Nafarelin—Nausea—Bleomycin—melanoma	0.00132	0.00213	CcSEcCtD
Nafarelin—Vomiting—Dactinomycin—melanoma	0.00132	0.00213	CcSEcCtD
Nafarelin—Rash—Dactinomycin—melanoma	0.00131	0.00211	CcSEcCtD
Nafarelin—Myalgia—Docetaxel—melanoma	0.0013	0.0021	CcSEcCtD
Nafarelin—Arthralgia—Docetaxel—melanoma	0.0013	0.0021	CcSEcCtD
Nafarelin—Chest pain—Docetaxel—melanoma	0.0013	0.0021	CcSEcCtD
Nafarelin—Dizziness—Carmustine—melanoma	0.00128	0.00207	CcSEcCtD
Nafarelin—Diarrhoea—Temozolomide—melanoma	0.00128	0.00207	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—CXCR2—melanoma	0.00127	0.00334	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—RHOB—melanoma	0.00127	0.00333	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—EDN1—melanoma	0.00126	0.00331	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—RAC2—melanoma	0.00125	0.00328	CbGpPWpGaD
Nafarelin—Oedema—Docetaxel—melanoma	0.00125	0.00201	CcSEcCtD
Nafarelin—Dizziness—Temozolomide—melanoma	0.00124	0.002	CcSEcCtD
Nafarelin—Vomiting—Carmustine—melanoma	0.00123	0.00199	CcSEcCtD
Nafarelin—Nausea—Dactinomycin—melanoma	0.00123	0.00199	CcSEcCtD
Nafarelin—Shock—Docetaxel—melanoma	0.00123	0.00198	CcSEcCtD
Nafarelin—Rash—Carmustine—melanoma	0.00122	0.00197	CcSEcCtD
Nafarelin—Dermatitis—Carmustine—melanoma	0.00122	0.00197	CcSEcCtD
Nafarelin—Headache—Carmustine—melanoma	0.00121	0.00196	CcSEcCtD
Nafarelin—Vomiting—Temozolomide—melanoma	0.00119	0.00192	CcSEcCtD
Nafarelin—Anorexia—Docetaxel—melanoma	0.00119	0.00192	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PLCB4—melanoma	0.00119	0.00312	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCL1—melanoma	0.00119	0.00312	CbGpPWpGaD
Nafarelin—Rash—Temozolomide—melanoma	0.00118	0.00191	CcSEcCtD
Nafarelin—Dermatitis—Temozolomide—melanoma	0.00118	0.0019	CcSEcCtD
Nafarelin—Headache—Temozolomide—melanoma	0.00117	0.00189	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CXCR2—melanoma	0.00115	0.00303	CbGpPWpGaD
Nafarelin—Nausea—Carmustine—melanoma	0.00115	0.00186	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—RAC2—melanoma	0.00114	0.00298	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Docetaxel—melanoma	0.00113	0.00183	CcSEcCtD
Nafarelin—Insomnia—Docetaxel—melanoma	0.00113	0.00182	CcSEcCtD
Nafarelin—Paraesthesia—Docetaxel—melanoma	0.00112	0.00181	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—WNT5A—melanoma	0.00112	0.00294	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TRRAP—melanoma	0.00112	0.00293	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CUL3—melanoma	0.00112	0.00293	CbGpPWpGaD
Nafarelin—Nausea—Temozolomide—melanoma	0.00111	0.0018	CcSEcCtD
Nafarelin—Dyspnoea—Docetaxel—melanoma	0.00111	0.00179	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—AKR1B10—melanoma	0.00109	0.00285	CbGpPWpGaD
Nafarelin—Decreased appetite—Docetaxel—melanoma	0.00108	0.00175	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—F2R—melanoma	0.00108	0.00284	CbGpPWpGaD
Nafarelin—Constipation—Docetaxel—melanoma	0.00106	0.00172	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—EDNRB—melanoma	0.00105	0.00275	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—F2RL1—melanoma	0.00101	0.00265	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—GAB2—melanoma	0.000988	0.0026	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—GNA11—melanoma	0.000988	0.0026	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—F2R—melanoma	0.000981	0.00258	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—melanoma	0.000969	0.00255	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—EDNRB—melanoma	0.00095	0.0025	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GRM3—melanoma	0.000949	0.00249	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCR4—melanoma	0.000929	0.00244	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—melanoma	0.000928	0.00244	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—GNAQ—melanoma	0.000919	0.00241	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KISS1—melanoma	0.000899	0.00236	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GAB2—melanoma	0.000897	0.00236	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GNA11—melanoma	0.000897	0.00236	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.000895	0.00235	CbGpPWpGaD
Nafarelin—Asthenia—Docetaxel—melanoma	0.000894	0.00144	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—melanoma	0.000883	0.00232	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—melanoma	0.000883	0.00232	CbGpPWpGaD
Nafarelin—Pruritus—Docetaxel—melanoma	0.000881	0.00142	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CXCR1—melanoma	0.000871	0.00229	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SKI—melanoma	0.000871	0.00229	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MC1R—melanoma	0.000858	0.00225	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—PIK3CA—melanoma	0.000857	0.00225	CbGpPWpGaD
Nafarelin—Diarrhoea—Docetaxel—melanoma	0.000852	0.00138	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—AKT3—melanoma	0.000848	0.00223	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCR4—melanoma	0.000844	0.00222	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GNAQ—melanoma	0.000834	0.00219	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—melanoma	0.000834	0.00219	CbGpPWpGaD
Nafarelin—Dizziness—Docetaxel—melanoma	0.000824	0.00133	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CCR7—melanoma	0.000823	0.00216	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GRM1—melanoma	0.000823	0.00216	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SUFU—melanoma	0.000802	0.00211	CbGpPWpGaD
Nafarelin—Vomiting—Docetaxel—melanoma	0.000792	0.00128	CcSEcCtD
Nafarelin—Rash—Docetaxel—melanoma	0.000785	0.00127	CcSEcCtD
Nafarelin—Dermatitis—Docetaxel—melanoma	0.000785	0.00127	CcSEcCtD
Nafarelin—Headache—Docetaxel—melanoma	0.00078	0.00126	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—AKT3—melanoma	0.00077	0.00202	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—melanoma	0.000766	0.00201	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RHOB—melanoma	0.000748	0.00197	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—BCL2L11—melanoma	0.000748	0.00197	CbGpPWpGaD
Nafarelin—Nausea—Docetaxel—melanoma	0.00074	0.00119	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—HDAC6—melanoma	0.000719	0.00189	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—EDN1—melanoma	0.000712	0.00187	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—melanoma	0.000709	0.00186	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CSF2—melanoma	0.000696	0.00183	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCR2—melanoma	0.000682	0.00179	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCL8—melanoma	0.000681	0.00179	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—melanoma	0.000679	0.00178	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RAC2—melanoma	0.000671	0.00176	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PRKCA—melanoma	0.000667	0.00175	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—WNT5A—melanoma	0.00066	0.00173	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—VEGFC—melanoma	0.00066	0.00173	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—EDN1—melanoma	0.000647	0.0017	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CSF2—melanoma	0.000632	0.00166	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—RAC1—melanoma	0.000619	0.00163	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PRKCA—melanoma	0.000606	0.00159	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—MAP2K2—melanoma	0.000593	0.00156	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—F2R—melanoma	0.00058	0.00152	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—RAC1—melanoma	0.000562	0.00148	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EDNRB—melanoma	0.000561	0.00147	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PTK2B—melanoma	0.000545	0.00143	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GAB2—melanoma	0.00053	0.00139	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GNA11—melanoma	0.00053	0.00139	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FLT1—melanoma	0.000528	0.00139	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CG—melanoma	0.000523	0.00137	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HDAC2—melanoma	0.000498	0.00131	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FOXO4—melanoma	0.000498	0.00131	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCR4—melanoma	0.000498	0.00131	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GNAQ—melanoma	0.000493	0.00129	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CG—melanoma	0.000475	0.00125	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SYK—melanoma	0.000463	0.00122	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CD—melanoma	0.00046	0.00121	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ITGAV—melanoma	0.000455	0.00119	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AKT3—melanoma	0.000455	0.00119	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NGFR—melanoma	0.000455	0.00119	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SOCS1—melanoma	0.000421	0.00111	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—MAP2K1—melanoma	0.00042	0.0011	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—S100B—melanoma	0.00042	0.0011	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CD—melanoma	0.000417	0.0011	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ERBB4—melanoma	0.000402	0.00106	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CB—melanoma	0.000401	0.00105	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CDKN2B—melanoma	0.000398	0.00105	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CD86—melanoma	0.000385	0.00101	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL8—melanoma	0.000385	0.00101	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EDN1—melanoma	0.000382	0.001	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FGF1—melanoma	0.000373	0.000981	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CSF2—melanoma	0.000373	0.000981	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—IL2—melanoma	0.000368	0.000967	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—E2F1—melanoma	0.000365	0.00096	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CB—melanoma	0.000364	0.000956	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PDGFRA—melanoma	0.000362	0.00095	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ITGB3—melanoma	0.000358	0.000941	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PRKCA—melanoma	0.000358	0.000941	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SPP1—melanoma	0.000351	0.000923	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAP2K2—melanoma	0.00035	0.00092	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCL8—melanoma	0.00035	0.000918	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL2—melanoma	0.000334	0.000878	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TERT—melanoma	0.000333	0.000875	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RAC1—melanoma	0.000332	0.000872	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HIF1A—melanoma	0.000318	0.000836	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KDR—melanoma	0.000304	0.0008	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FN1—melanoma	0.000293	0.00077	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NOTCH1—melanoma	0.000287	0.000753	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CD80—melanoma	0.000281	0.000738	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CG—melanoma	0.00028	0.000737	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—APC—melanoma	0.00028	0.000737	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KIT—melanoma	0.00028	0.000737	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—NRAS—melanoma	0.00028	0.000737	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EGF—melanoma	0.000277	0.000728	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—MAPK3—melanoma	0.000269	0.000706	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—BRAF—melanoma	0.000264	0.000693	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IGF1—melanoma	0.000257	0.000675	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—MAPK1—melanoma	0.000256	0.000671	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—EGFR—melanoma	0.000256	0.000671	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAP2K1—melanoma	0.000248	0.000652	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CD—melanoma	0.000247	0.000648	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CA—melanoma	0.000244	0.000642	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—KRAS—melanoma	0.000241	0.000634	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FGF2—melanoma	0.000236	0.00062	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CA—melanoma	0.000222	0.000583	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MDM2—melanoma	0.000221	0.00058	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ERBB2—melanoma	0.000218	0.000572	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CB—melanoma	0.000215	0.000565	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCL8—melanoma	0.000207	0.000543	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—HRAS—melanoma	0.000205	0.000539	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CDKN1B—melanoma	0.000202	0.00053	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AKT1—melanoma	0.000199	0.000524	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CASP3—melanoma	0.000198	0.000519	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL2—melanoma	0.000197	0.000519	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL6—melanoma	0.000196	0.000516	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCND1—melanoma	0.000192	0.000505	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CTNNB1—melanoma	0.000191	0.000501	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MMP9—melanoma	0.000187	0.000491	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CDKN1A—melanoma	0.000186	0.000489	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PTEN—melanoma	0.000186	0.000488	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NFKB1—melanoma	0.000185	0.000486	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AKT1—melanoma	0.000181	0.000476	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—VEGFA—melanoma	0.000168	0.000441	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—STAT3—melanoma	0.000166	0.000436	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NRAS—melanoma	0.000166	0.000435	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAPK3—melanoma	0.000159	0.000417	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MYC—melanoma	0.000154	0.000405	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAPK1—melanoma	0.000151	0.000397	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EGFR—melanoma	0.000151	0.000397	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KRAS—melanoma	0.000143	0.000375	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CA—melanoma	0.000131	0.000344	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TP53—melanoma	0.000127	0.000333	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HRAS—melanoma	0.000121	0.000318	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL6—melanoma	0.000116	0.000305	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AKT1—melanoma	0.000107	0.000281	CbGpPWpGaD
